Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX – Get Free Report)’s stock price was up 998% during trading on Wednesday . The stock traded as high as $0.60 and last traded at $0.5490. Approximately 84,299 shares changed hands during mid-day trading, an increase of 335% from the average daily volume of 19,387 shares. The stock had previously closed at $0.05.
Eloxx Pharmaceuticals Stock Up 5.9%
The company has a market cap of $1.83 million, a PE ratio of -0.26 and a beta of -1,907.33. The firm’s fifty day simple moving average is $0.12.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc (NASDAQ: ELOX) is a clinical‐stage biopharmaceutical company focused on developing precision medicines for rare genetic diseases caused by nonsense mutations. Its lead candidate, ELX-02, is a novel small molecule designed to enable ribosomal read-through of premature stop codons and restore production of full-length, functional proteins. The company’s initial therapeutic targets include cystic fibrosis and cystinosis, with ELX-02 advancing through Phase 2 clinical studies in cystic fibrosis and Phase 1/2 trials in cystinosis.
In addition to ELX-02, Eloxx is advancing second-generation read-through compounds in its discovery pipeline to broaden treatment opportunities for patients with other nonsense mutation-driven disorders.
Read More
- Five stocks we like better than Eloxx Pharmaceuticals
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
- Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
